title: Mechanisms of inverse agonist action at D2 dopamine receptors.
abstract: Mechanisms of inverse agonist action at the D2(short) dopamine receptor have been examined. Discrimination of G-protein-coupled and -uncoupled forms of the receptor by inverse agonists was examined in competition ligand-binding studies versus the agonist [3H]NPA at a concentration labelling both G-protein-coupled and -uncoupled receptors. Competition of inverse agonists versus [3H]NPA gave data that were fitted best by a two-binding site model in the absence of GTP but by a one-binding site model in the presence of GTP. K(i) values were derived from the competition data for binding of the inverse agonists to G-protein-uncoupled and -coupled receptors. K(coupled) and K(uncoupled) were statistically different for the set of compounds tested (ANOVA) but the individual values were different in a post hoc test only for (+)-butaclamol. These observations were supported by simulations of these competition experiments according to the extended ternary complex model. Inverse agonist efficacy of the ligands was assessed from their ability to reduce agonist-independent [35S]GTP gamma S binding to varying degrees in concentration-response curves. Inverse agonism by (+)-butaclamol and spiperone occurred at higher potency when GDP was added to assays, whereas the potency of (-)-sulpiride was unaffected. These data show that some inverse agonists ((+)-butaclamol, spiperone) achieve inverse agonism by stabilising the uncoupled form of the receptor at the expense of the coupled form. For other compounds tested, we were unable to define the mechanism.
authors.affiliation: School of Animal and Microbial Sciences, University of Reading, Whiteknights, Reading RG6 6AJ.
authors.forename: David J
authors.initials: DJ
authors.lastname: Roberts
authors.forename: Philip G
authors.initials: PG
authors.lastname: Strange
mesh_terms: D000818:Animals; D001058:Apomorphine / Q000031:analogs & derivatives* / Q000378:metabolism; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D065127:Dopamine D2 Receptor Antagonists; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000378:metabolism; D006153:Guanosine Diphosphate / Q000494:pharmacology; D008024:Ligands; D011485:Protein Binding; D011869:Radioligand Assay; D017448:Receptors, Dopamine D2 / Q000819:agonists* / Q000378:metabolism*; D014316:Tritium
chemical_list: D065127:Dopamine D2 Receptor Antagonists; D008024:Ligands; D017448:Receptors, Dopamine D2; D014316:Tritium; D006153:Guanosine Diphosphate; D016244:Guanosine 5'-O-(3-Thiotriphosphate); C009074:N-n-propylnorapomorphine; D001058:Apomorphine
references.citation: J Neurochem. 2000 Jan;74(1):347-57
references.pmid: 10617139
references.citation: J Biol Chem. 1951 Nov;193(1):265-75
references.pmid: 14907713
references.citation: Br J Pharmacol. 2000 Jul;130(5):987-96
references.pmid: 10882382
references.citation: Mol Pharmacol. 2001 Mar;59(3):532-42
references.pmid: 11179449
references.citation: Pharmacol Rev. 2001 Mar;53(1):119-33
references.pmid: 11171942
references.citation: J Neurochem. 2001 Apr;77(2):493-504
references.pmid: 11299312
references.citation: Trends Pharmacol Sci. 2002 Feb;23(2):89-95
references.pmid: 11830266
references.citation: J Biol Chem. 2002 Sep 27;277(39):36577-84
references.pmid: 12145300
references.citation: J Pharmacol Exp Ther. 2003 Jan;304(1):380-90
references.pmid: 12490615
references.citation: Br J Pharmacol. 2003 Mar;138(5):775-86
references.pmid: 12642378
references.citation: Br J Pharmacol. 2003 Mar;138(6):1129-39
references.pmid: 12684269
references.citation: Biochem Pharmacol. 2004 May 1;67(9):1657-65
references.pmid: 15081865
references.citation: Biochem Pharmacol. 2004 Jun 1;67(11):2039-45
references.pmid: 15135301
references.citation: Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
references.pmid: 4202581
references.citation: J Biol Chem. 1982 Jun 10;257(11):6351-61
references.pmid: 6176582
references.citation: Proc Natl Acad Sci U S A. 1989 Oct;86(19):7321-5
references.pmid: 2552439
references.citation: Mol Pharmacol. 1992 Mar;41(3):549-60
references.pmid: 1312216
references.citation: J Neurochem. 1993 Jan;60(1):372-5
references.pmid: 8417160
references.citation: J Biol Chem. 1993 Mar 5;268(7):4625-36
references.pmid: 8095262
references.citation: Trends Pharmacol Sci. 1993 Aug;14(8):303-7
references.pmid: 8249148
references.citation: Mol Pharmacol. 1994 Mar;45(3):524-31
references.pmid: 8145737
references.citation: Br J Pharmacol. 1997 Jun;121(4):731-6
references.pmid: 9208141
references.citation: J Biol Chem. 1997 Aug 29;272(35):22330-9
references.pmid: 9268384
references.citation: Mol Pharmacol. 1999 Nov;56(5):858-66
references.pmid: 10531388
references.citation: Trends Pharmacol Sci. 1997 Oct;18(10):355-62
references.pmid: 9357320
references.citation: J Neurochem. 1997 Dec;69(6):2589-98
references.pmid: 9375693
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1997 Nov;356(5):551-61
references.pmid: 9402034
references.citation: Mol Pharmacol. 1997 Dec;52(6):1137-49
references.pmid: 9396784
references.citation: J Biol Chem. 1998 Jul 3;273(27):16865-73
references.pmid: 9642247
references.citation: J Biol Chem. 1998 Jul 17;273(29):17979-82
references.pmid: 9660746
references.citation: J Neurochem. 1998 Aug;71(2):799-807
references.pmid: 9681472
references.citation: Mol Pharmacol. 1998 Aug;54(2):435-44
references.pmid: 9687586
references.citation: Mol Pharmacol. 1999 Mar;55(3):473-80
references.pmid: 10051530
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2000 May;361(5):498-504
references.pmid: 10832603